Given their pivotal role in various physiological processes, GPCRs are prominent targets in drug development. Approximately 34% of all FDA-approved drugs target GPCRs, underscoring their importance. By understanding how toxins interact with these receptors, researchers can design safer and more effective drugs that either mimic or block the action of natural ligands.
